Filing Details

Accession Number:
0001209191-14-074332
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-12-10 21:14:05
Reporting Period:
2014-12-10
Filing Date:
2014-12-10
Accepted Time:
2014-12-10 21:14:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1062822 Lexicon Pharmaceuticals Inc. LXRX Pharmaceutical Preparations (2834) 760474169
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1053890 Raymond Debbane C/O Ulys, L.l.c.
750 Lexington Avenue, 30Th Floor
New York NY 10022
Yes No Yes No
1340098 Ulys, L.l.c. 750 Lexington Avenue, 30Th Floor
New York NY 10022
Yes No Yes No
1378005 C.v. Invus Marten Meesweg 25
Rotterdam P7 3068AV
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-12-10 315,896 $0.90 30,098,505 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 34,685 Direct
Footnotes
  1. These securities are directly held by Invus C.V.
  2. These securities are directly held by Mr. Raymond Debbane.
  3. Ulys, L.L.C. is the general partner of Invus C.V., and Mr. Raymond Debbane is the sole member of Ulys, L.L.C.
  4. Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
  5. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.8946 to $0.9093, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.